Erythropoietin and anemia: Biological markers that cannot be ignored in diabetic retinopathy

Medical Hypotheses

Volumn 78, Issue 4, 2012, Pages 555-556

  DeNiro, Michael ^a   Al Mohanna, Futwan A ^b,c  

^a KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ERYTHROPOIETIN; HEMOGLOBIN; VASCULOTROPIN;

ANEMIA; ANTIANGIOGENIC THERAPY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; HEMATOCRIT; HUMAN; LETTER; NEUROPROTECTION; PATIENT SAFETY; RETINA CELL; RETINA ISCHEMIA; RETINA NEOVASCULARIZATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT;

ANEMIA; ANGIOGENESIS INHIBITORS; BIOLOGICAL MARKERS; DIABETIC RETINOPATHY; ERYTHROPOIETIN; HUMANS; ISCHEMIA; MODELS, BIOLOGICAL;

EID: 84858158024     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.01.026     Document Type: Letter

References (4)

1. Ritz E. Anemia and diabetic nephropathy. Curr Diab Rep 2006, 6:469-472.
2. Dunst J, Becker A, Lautenschläger C, Markau S, Becker H, Fischer K, Haensgen G. Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF) Strahlenther Onkol 178 (2002) 436-441.
3. Thomas MC. Anemia in diabetes: marker or mediator of microvascular disease?. Nat Clin Pract Nephrol 2007, 3:20-30.
4. Feldman DR, Ginsberg MB, Flombaum C, Hassoun H, Velasco S, Fisher P, et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Onco. 2006;26 [May 20 suppl; abstr 5100].